Teva Neuroscience just launched a Spanish Parkinson’s disease Web site, www.azilect.com/espanol. There are not a lot of Hispanic resources available, so Teva wanted to take the lead in providing useful information in Spanish online.
For Immediate Release
TEVA NEUROSCIENCE LAUNCHES SPANISH PARKINSON’S DISEASE PATIENT AND CAREGIVER WEB SITE
Kansas City, MO (Sep. 29, 2008) — In recognition of Hispanic Heritage Month, Teva Neuroscience, Inc., marketers of the once-daily Parkinson’s disease (PD) drug AZILECT ® (rasagiline tablets), today announced the launch of the Spanish version of their patient and caregiver resource Web site, azilect.com/espanol. The Spanish Web site was created to provide important information and resources to members of the Hispanic community, living in the U.S., who are affected by PD, an age-related degenerative disorder of the brain.
“Unfortunately, there are not a lot of resources for Spanish-speaking patients dealing with Parkinson’s disease,” said Dr. Ramon L. Rodriguez, director of clinical services at the University of Florida’s Movement Disorders Center. “Even though there is no cure for Parkinson’s, it is important for patients to learn how to live well through a combination of activities and treatments that can help control the symptoms of the disease.”
The Spanish Web site, azilect.com/espanol, is a comprehensive resource that provides important information to help patients and families with the physical and emotional effects of PD. Spanish-speaking visitors will be able to access a wide range of information and resources, including:
· Basic disease information and treatment options
· Signs and symptoms of the disease
· Tips on living well through a combination of treatment, activities, and support
· Downloadable worksheets and links to various other resources
· Caregiver information
Additionally, visitors will have access to a downloadable version of the recently released “Hacia adelante” resource guide. The easy-to-use guide is a useful tool that helps people affected by PD understand more about the disease, learn how to live well despite the diagnosis, and research various treatment options.
“We are pleased to bring these much needed resources to the Spanish-speaking community living in the U.S.,” said Teva Neuroscience product manager, Mike Sheehy. “We believe it is important to provide Spanish-language materials and information that help people manage diseases, such as PD, to this important and growing community."
Teva Neuroscience is headquartered in Kansas City, MO. For additional information about Teva’s Spanish resources for PD or AZILECT, visit azilect.com/espanol.
Contacts:
Courtney Fadler, Fleishman-Hillard, 816-512-2306, [email protected]
Carlos Casas, Fleishman-Hillard, 816-512-2344, [email protected]
Comments